Ukuhlunga kwe-Euflexxa Kusetshenziswa Ku-Viscosupplementation
I-Euflexxa iyisisombululo se hyaluronan ehlanzekile kakhulu (ebizwa ngokuthi i-hyaluronic acid noma i-sodium hyaluronate) e-saline. I-hyaluronan e-Euflexxa isuswa amangqamuzana amabhaktheriya. Kuyinto yokuqala ye-hyaluronan engayitholakali.
I-Euflexxa ingenye yama-hyaluronates asetshenziselwa i- viscosupplementation . I-Euflexxa ijojowe ngqo emadolweni ekuhlanganyeleni ukubuyisela izindawo zokugcoba nokugcoba ezijwayelekile zamanzi abizayo (okungukuthi, i-joint fluid).
Amalunga amathintekayo ashintshwe yi-osteoarthritis alahlekelwa yizindawo zokugcoba.
Isiboniso se-Euflexxa
I-Euflexxa yamukelwa yi-US FDA ngoDisemba 3, 2004 yokwelapha ubuhlungu bamadolo obuhlotshaniswa ne- osteoarthritis ezigulini eziye zahluleka ukuphendula ukwelapha okungapheli komuthi (isib. Ukwelashwa ngokomzimba) nakuma-analgesics alula, njenge- acetaminophen . I-Euflexxa ilawulwa njengamachungechunge ama- intra-articular amathathu amasonto onke.
Ukuqhathaniswa kwe-Euflexxa
Abantu abane-hypersensitivity eyaziwa ngemikhiqizo ye-hyaluronan akufanele baphathwe nge-Euflexxa. Futhi, abantu abanesifo ekuhlanganyeleni ngamadolo, okunye ukutheleleka, noma isifo esikhumbeni endaweni lapho umjovo okwenzeka khona akufanele uphathwe nge-Euflexxa.
Imiphumela Ejwayelekile Yomphakathi kanye Nemicimbi Ebizayo
Izenzakalo ezivame kakhulu ezihlobene ne-Euflexxa ukwelashwa phakathi nezifundo zomtholampilo zazihlanganisa i-arthralgia (ubuhlungu obuhlangene), ubuhlungu bomhlane, ubuhlungu ezandleni noma emilenzeni, ubuhlungu be-musculoskeletal, nokuvuvukala okuhlangene.
Izenzakalo ezimbi ezingase zenzeke nganoma yikuphi umjovo we-intra-articular zihlanganisa i-arthralgia, ukuvuvukala okuhlangene, ukuxuba okuhlangene, ubuhlungu be-injection site kanye ne-arthritis.
Ukuqapha nokuxwayiswa
Ngemuva kokuthola umjovo we-intra-articular we-Euflexxa, njengokungathi noma yimuphi umjovo ohlangene, kunconywa ukuthi isiguli sigweme imisebenzi enzima noma imisebenzi yokulinganisela isikhathi eside amahora angu-48.
Futhi, kufanele kuqashelwe ukuthi ubuhlungu noma ukuvuvukala kungenzeka ngemuva komjovo, kodwa kuzokwehlisa emva kwesikhathi esifushane.
Ukuphepha nokusebenza kwe-Euflexxa akukwakhiwa kwabesifazane abakhulelwe. Ayaziwa ukuthi u-Euflexxa uyadliwa ngobisi obuningi ngoba ukuphepha nokusebenza akuzange kusungulwe ekuqotheni abesifazane. Futhi, ukuphepha nokusebenza kwe-Euflexxa akukwakhiwa ezinganeni.
Okubalulekile
Amanye ama-viscosupplements avunyelwe i-FDA, kanye nosuku avunyelwe ngalo, afaka:
- Hyalgan 05/28/1997
- I-Synvisc 08/08/1997
- I-Supartz 01/24/2001
- I-Orthovisc 02/05/2004
I-American Association of Orthopedic Surgeons (AAOS) yaphetha ngokuthi, "Nakuba ezinye iziguli zibika ukuphazamiseka kwezimpawu ze-arthritis nge-viscosupplementation, le nqubo ayikaze iboniswe ukuthi iguqule inqubo ye-arthritic noma ibuye ikhule kabusha." Ukusebenza kwe-viscosupplementation ekwelapheni i-arthritis akucaci Kuye kwaphakanyiswa ukuthi i-viscosupplementation iphumelela kakhulu uma i-arthritis isesimweni sayo sokuqala (okuncane kuya komlinganiso), kepha ucwaningo olwengeziwe luyadingeka ukuze lusekele lokhu. Ucwaningo lwama-viscosupplementation nemiphumela yaso yesikhathi eside luqhubeka. "
> Imithombo:
> I-Viscosupplementation Treatment for Knee Arthritis. I-OrthoInfo (AAOS). Ibuyekezwe ngoJuni 2015.
> Euflexxa. Ukubeka imininingwane. July 2017
> I-Ferring Pharmaceuticals Imemezela Ukuqaliswa Kwe-Euflexxa Ye-Osteoarthritis Knee Pain, i-News Release Ferring Pharmaceuticals Inc., ngoNovemba 14, 2005.